Sugi Predict

Sugi Predict / Compounds / SCHEMBL1418367

SCHEMBL1418367

SCHEMBL1418367

CN1c2ccccc2Sc2cc(C=O)ccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.61
▸ NOX1 Q9Y5S8 8/20 0.59
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ ADRA2A P08913 1/20 0.59
▸ ADRA2B P18089 1/20 0.59
▸ ADRA2C P18825 1/20 0.59
▸ CHRM3 P20309 1/20 0.59
▸ SLC6A2 P23975 1/20 0.59
▸ HTR2C P28335 1/20 0.59
▸ SLC6A4 P31645 1/20 0.59
▸ DRD3 P35462 1/20 0.59
▸ HTR2B P41595 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ MAPT P10636 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ APP P05067 4/20 0.47
▸ FNTA P49354 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30678529 0.92 NOX1 (0.46) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL2495259 0.92 NOX1 (0.46) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL31286280 0.85 MAOA (0.54) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL28332097 0.85 MAOA (0.54) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL30419778 0.84 MAOA (0.61) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL11592363 0.84 MAOA (0.61) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL27062254 0.84 MAOA (0.61) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL28050075 0.84 NOX1 (0.41) MAOANOX1L3MBTL1MEN1ADRA2A
SCHEMBL29376040 0.84 PDF (0.48) NOX1L3MBTL1MEN1ADRA2AADRA2B
SCHEMBL25842328 0.84 PDF (0.48) NOX1L3MBTL1MEN1ADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117510434-A 10-methyl-7-nitro-10H-phenothiazine-3-formaldehyde acetyl substituent oxime and preparation method and application thereof 中原工学院 2024-02-06 — — CN claimed
CN-106045986-B novel phenothiazine derivative and preparation method and application thereof 广东工业大学 2019-12-06 — — CN claimed
US-20250382442-A1 CROSSLINKABLE ACRYLIC RUBBER COMPOSITION UNIMATEC CO., LTD. (JP) 2025-12-18 — — US disclosed
CN-119421878-B Method for separating phenothiazine derivative compound 优迈特株式会社 2025-05-02 — — CN disclosed
US-20250115694-A1 ACRYLIC ELASTOMER COPOLYMER UNIMATEC CO., LTD. (JP) 2025-04-10 — — US disclosed
EP-4527887-A1 CROSSLINKABLE ACRYLIC RUBBER COMPOSITION Unimatec Co., Ltd. (JP) 2025-03-26 — — EP disclosed
CN-119421878-A Method for separating phenothiazine derivative compound 优迈特株式会社 2025-02-11 — — CN disclosed
CN-119173578-A Crosslinkable acrylic rubber composition 优迈特株式会社 2024-12-20 — — CN disclosed
CN-119101502-A Preparation method of BPQD@PDA-F fluorescent probe for detecting and regulating Abeta aggregation and performance research 石河子大学 2024-12-10 — — CN disclosed
EP-4442719-A1 ACRYLIC ELASTOMER COPOLYMER Unimatec Co., Ltd. (JP) 2024-10-09 — — EP disclosed
CN-118339208-A Acrylic elastomeric copolymers 优迈特株式会社 2024-07-12 — — CN disclosed
US-7700630-B2 Heterocyclic compounds, methods for the preparation thereof, and uses thereof MEMORY PHARMACEUTICALS CORPORATION (US) 2010-04-20 — — US disclosed
US-20090105215-A1 3-Quinolin-2-ylmethylene-3,4,5,6-terahydro[2,3']bipyridinyl; for therapy and prophylaxis of psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system HERBERT BRIAN 2009-04-23 — — US disclosed
US-7244745-B2 Heterocyclic compounds, methods for the preparation thereof, and uses thereof MEMORY PHARMACEUTICALS CORP. (US) 2007-07-17 — — US disclosed
EP-1531820-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Memory Pharmaceuticals Corporation (US) 2005-05-25 — — EP disclosed
US-20040229868-A1 Heterocyclic compounds, methods for the preparation thereof, and uses thereof MEMORY PHARMACEUTICALS CORP. 2004-11-18 — — US disclosed
WO-2004019943-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES MEMORY PHARMACEUTICALS CORPORATION (US) 2004-03-11 — — WO disclosed
US-5830902-A SQUALENE SYNTHASE INHIBITOR YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1998-11-03 — — US disclosed
CN-1177353-A Novel quinuclidine derivatives having tricyclic fused hereto ring YAMANOUCHI PHARMA CO LTD (JP) 1998-03-25 — — CN disclosed
EP-0812840-A1 NOVEL QUINUCLIDINE DERIVATIVES HAVING TRICYCLIC FUSED HETERO RING YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1997-12-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229868-A1 Heterocyclic compounds, methods for the preparation thereof, and uses thereof CHRNA1, CHRNA4, CHRNA3 MAOA 224/4885NOX1 420/4885L3MBTL1 4749/4885
US-20090105215-A1 3-Quinolin-2-ylmethylene-3,4,5,6-terahydro[2,3']bipyridinyl; for therapy and prophylaxis of psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system CHRNA3, CHRNA2, CHRNA5 MAOA 370/4885NOX1 2122/4885L3MBTL1 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.